SHIELD THERAPEUTICS PLC – Shield Assumes Full Control Of Accrufer In The Us
RNS Number : 4923S Shield Therapeutics PLC 27 August 2026 The information contained within this announcement is deemed by
Read More
SHIELD THERAPEUTICS PLC – Interim Results For The Six Months Ended 30 Jun 26
RNS Number : 3979R Shield Therapeutics PLC 20 August 2026 Shield Therapeutics plc (“Shield” or the “Company” or
SHIELD THERAPEUTICS PLC – Accrufer R Phase 3 Pediatric Trial Published
RNS Number : 0572O Shield Therapeutics PLC 28 July 2026 Shield Therapeutics plc (“Shield” or the “Company” or
SHIELD THERAPEUTICS PLC – Q1 2026 Trading Update
RNS Number : 6954C Shield Therapeutics PLC 01 May 2026 The information contained within this announcement is deemed by
SHIELD THERAPEUTICS PLC – Enrollment In Phase Ii Clinical Trial For Accrufer
RNS Number : 9946B Shield Therapeutics PLC 27 April 2026 Shield Therapeutics plc (“Shield” or the “Company” or the
SHIELD THERAPEUTICS PLC – Audited Results For Year Ended 31 December 2025
RNS Number : 8611Z Shield Therapeutics PLC 09 April 2026 Shield Therapeutics plc (“Shield” or the “Company” or the
Shield Therapeutics PLC – STX – Half-year Report
London, UK, 16 September 2020: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces its unaudited interim results for the six months ended 30 June 2020.
Four AIM strugglers with recovery potential
Our award-winning AIM expert discusses how some of 2019’s worst performers could bounce back this year.
These small-caps could thrive after Brexit
There will be winners in the event of a no-deal Brexit. Our AIM expert identifies possible candidates.
Shield Therapeutics PLC – Major extension to approval in Switzerland
Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now include treatment of all adults with iron deficiency (ID) with or without anaemia.